开立医疗收盘下跌2.12%，滚动市盈率254.73倍，总市值128.08亿元

Company Overview - The company, Shenzhen Kaili Biomedical Technology Co., Ltd., specializes in the independent research, production, and sales of medical diagnostic and treatment equipment [1] - The main products include medical ultrasound diagnostic equipment, digestive and respiratory endoscopes, minimally invasive surgical products, and cardiovascular interventional products [1] - The company has over 20 years of experience in the ultrasound industry and is recognized as a high-tech enterprise with leading core technologies in color Doppler ultrasound [1] Financial Performance - For Q1 2025, the company reported a revenue of 430 million yuan, a year-on-year decrease of 10.29% [2] - The net profit for the same period was 8.07 million yuan, reflecting a significant year-on-year decline of 91.94% [2] - The gross profit margin stood at 63.19% [2] Market Position - The company's rolling price-to-earnings (PE) ratio is 254.73, significantly higher than the industry average of 49.45 and the median of 35.92 [2] - The total market capitalization of the company is 12.808 billion yuan [1] - Among 38 institutions holding shares, there are 35 funds, 1 brokerage, 1 social security fund, and 1 other entity, with a total holding of 52.883 million shares valued at 1.539 billion yuan [1] Competitive Landscape - The company ranks second in market share among domestic manufacturers in the ultrasound sector and tenth globally, indicating strong brand influence and competitiveness [1]